Dulaglutide
Glucose Intolerance
University of Pennsylvaniaprotein_peptidePhase 4 / ApprovedActive
BBB
75/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 61/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Glucose Intolerance cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Dexmedetomidine Pontificia Universidad Catolica de Chile | Phase 4 | BB |
Vibisone The University of Texas Health Science Center, Houston | Phase 4 | BB |
Nepenthe Washington University School of Medicine | Phase 4 | BB |
Fentanyl Pontificia Universidad Catolica de Chile | Phase 4 | BB |
Candesartan Fundación Cardiovascular de Colombia | Phase 4 | BB |
View all 15 →
Same molecule, other indications
Dulaglutide is also rated in:
metabolic dysfunction-associated steatotic liver diseaseActive
BB
Indicative · Phase 4
65 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →